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1. Introduction
  Anthrax, a fatal bacterial disease, is caused by the gram-
positive, spore-forming bacterium, Bacillus anthracis (B. 
anthracis)[1, 2]. The disease normally occurs in herbivores, 
and human infections usually occur after contacting with 
infected animals or their contaminated products[3]. Also, 
anthrax may be used as a biological weapon[4]. The two 
principal virulence factors of B. anthracis are a poly-毭
-D-glutamic acid capsule and the anthrax toxin. These 
factors are encoded by virulence plasmids pXO2 and pXO1, 
respectively[5]. Anthrax toxin consists of three components: 
protective antigen (PA, 83 kDa), edema factor (EF, 89 
kDa), and lethal factor (LF, 85 kDa). EF is a calcium and 
calmodulin-dependent adenylate cyclase that increases 
intracellular cAMP levels. LF is a zinc metalloprotease 
that cleaves the N-terminal of mitogen-activated protein 
kinase kinases (MAPKKs). PA83 binds to a cell receptor and 
then is cleaved by furin-like proteases into PA20 and PA63 
fragments. PA63 forms a ring-shaped heptamer structure at 
the cell surface and interacts with EF or LF. This complex 
is internalized by receptor-mediated endocytosis, where 
at low pH of the endosome, PA heptamer forms a pore 
that inserts EF and LF into the cytoplasm of the target 
cell[6-9]. Individually, these components are not toxic, 
but the combinations of PA with EF or LF produce edema 
toxin or lethal toxin, respectively[10-12]. The lethal toxin 
causes death in animal models and the edema toxin causes 
local edema at the inoculation site[13].With respect to the 
acuteness of this disease, immunization before challenge is 
of crucial importance. The current licensed human vaccines 
are produced in the United States and United Kingdom. 
The US vaccine (AVA) is an aluminum hydroxide-adsorbed 
cell-free culture filtrate of a non-encapsulated strain 
(V770-NP1-R), and the UK vaccine is an alum-precipitated 
cell-free culture filtrate of a Sterne strain (34F2)[14,15]. These 
vaccines can cause local side effects, and several boosters 
are required to maintain protective immunity. Therefore, 
an improved, effective, and safe human vaccine is needed 
against anthrax. PA is the major immunogenic component 
in the current licensed human vaccines[16,17]. Thus, purified 
recombinant PA can be used for development of a human 
subunit vaccine against anthrax. Researchers have cloned 
and expressed the PA gene in several bacterial hosts. In the 
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present study, we developed a vector system for high level 
expression of rPA in Escherichia coli(E. coli) DH5毩 host 
strain.
2. Materials and methods
2.1. Reagents and chemicals
  T4  l i gase ,  res t r i c t i on  enzymes ,  i sopropy l-毬
-D-thiogalactopyranoside (IPTG), 1kb DNA ladder, and 
protein molecular weight marker were obtained from 
Fermentas (USA). Plasmid isolation kit and gel extraction kit 
were from Qiagen (Germany). Taq polymerase and dNTPs 
were from Cinnagen (Iran). Oligonucleotide primers were 
synthesized by TAG Copenhagen (Denmark). Secondary 
antibody and nitrocellulose membranes were from 
Komabiotech (Korea). Anti-PA monoclonal antibody was 
from Hytest (Finland). All chemicals were purchased from 
Merck (Germany), Sigma (USA), and Applichem (Germany).
2.2. Bacteria, plasmid and culture media
  B. anthracis Sterne strain 34F2 was obtained from anthrax 
live spore vaccine (RAZI vaccine and serum research 
institute, Iran). E. coli DH5毩 host strain was obtained from 
Cinnagen. The pMAL-c2X expression vector was purchased 
from New England Biolabs (USA). E. coli DH5毩 was grown 
in LB broth or LB agar (Merck) and B. anthracis Sterne strain 
was grown in brain-heart infusion (BHI) medium (Difco, 
USA). When required, LB medium was supplemented with 
100 毺g/mL ampicillin.
2.3. Bacterial growth and isolation of plasmid DNA
  B. anthracis was grown overnight in BHI medium at 37 曟,
180 rpm. Isolation of pXO1 plasmid was carried out by 
alkaline lysis method[18].
2.4. Polymerase chain reaction (PCR)
  The coding region of PA (2.2 kb) was amplified by PCR 
using the oligonucleotide primers 5’- G C C G G G A T C C 
G A A G T T A A A C A G G A G A A C-3’, containing BamHI 
restriction site (underlined) and 5’-G C C G G T C G A C T A G 
A A T T A C C T T A  T C C-3’, containing SalI restriction site 
(underlined) with pXO1 as a template. PCR was performed 
in a Eppendorf thermal cycler (Germany) and in a total 
volume of 50 毺L(1.5 mM MgCl2, 1 pmol of each primers, 
0.2 mM dNTPs, and 2.5 unit Taq polymerase). Denaturation, 
annealing, and extension were carried out at 94 曟 for 60 s, 
49 曟 for 60 s, and 72 曟 for 90 s, for 35 cycles. The PCR 
product was analyzed by 1% agarose gel electrophoresis.
2.5. Cloning of PA gene into E. coli DH5毩
  pMAL-c2X plasmid was isolated and purified by plasmid 
isolation kit. The PCR product was purified from the agarose 
gel by gel extraction kit. The purified PCR product and 
pMAL-c2X vector were digested with BamHI and SalI 
restriction enzymes. The digested products were analyzed 
on 1% agarose gel and purified by gel extraction kit. The 
digested PCR product was ligated into pMAL-c2X vector 
using T4 ligase and incubated at 4 曟 overnight. The pMAL-
c2X-PA vector was transformed into E. coli DH5毩 host 
strain by one-step PEG transformation method[18]. The 
colonies on LB agar supplemented with ampicillin were 
screened by PCR analysis using PA gene specific primers. 
Plasmid DNA was miniprepared from positive clones and 
isolation of PA gene fragment was analyzed on 1% agarose 
gel by restriction enzyme digestion.
2.6. Expression of the recombinant fusion protein
  A positive clone was selected and grown overnight in 5 mL 
LB broth supplemented with ampicillin at 37 曟, 180 rpm. 
100 毺L of this culture was inoculated to 10 mL of LB 
broth supplemented with glucose and ampicillin. Bacterial 
culture was grown at 37 曟, 180 rpm and induced with 0.3 
mM IPTG at OD600 equal to 0.5. The culture samples were 
collected at 2, 4 and 6 h after IPTG induction. The cells were 
harvested by centrifugation at 13 000 g for 2 min and the 
pellet resuspended in sample buffer. Samples were boiled 
in sample buffer for 5 min and centrifuged at 13 000 g for 
1 min. The supernatant of samples was analyzed by SDS-
PAGE on 10% polyacrylamide gel followed by Coomassie 
Brilliant Blue staining. The recombinant MBP-PA fusion 
protein was also detected by Western blotting using an 
anti-PA monoclonal antibody. After SDS-PAGE of samples, 
proteins were transferred to nitrocellulose membrane 
by electrophoresis at 60 V for 4 h using transfer buffer. 
The membrane was blocked with 5% skim milk in PBS 
overnight. After washing with PBST (PBS containing 0.05% 
Tween 20) for three times, each for 5 min, the membrane 
was incubated with 1:10 000 dilution of anti-PA monoclonal 
antibody in the PBST containing 2% skim milk for 1 h. 
The membrane was washed with PBST as described above 
and incubated with 1:1 000 dilution of goat anti-mouse 
horseradish peroxidase-conjugated polyclonal antibody 
in the PBST containing 2% skim milk for 1 h. Finally, the 
membrane was washed with PBST for three times, each for 
10 min, and HRP-conjugated secondary antibody was 
detected using 4-chloro-1-naphthol and H2O2.
3. Results
3.1. Construction of recombinant plasmid
  For expression of the B. anthracis protective antigen 
protein in E. coli, the PA gene was amplified by PCR using 
specific primers containing BamHI and SalI restriction 
sites and pXO1 plasmid as template. The PCR product was 
confirmed on agarose gel and a DNA fragment with expected 
size (2.2 kb) was observed. After PCR amplification, the PA 
gene was ligated into pMAL-c2X vector using BamHI and 
SalI restriction sites. In this recombinant construct, the PA 
gene was fused to malE gene that encodes the maltose-
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binding protein (MBP) and both genes were under control of 
Ptac promoter.
3.2. Transformation and clone screening
  The pMAL-c2X expression vector was transformed into E. 
coli DH5毩 using one-step PEG method. The colonies were 
screened by PCR and positive clones were confirmed by 
presence of a 2.2 kb DNA fragment on agarose gel(Figure 1). 
The purified recombinant plasmids of positive clones were 
digested with BamHI and SalI, and the insert was released 
from plasmids that corresponded to the PA gene size (Figure 
2).
1             2                3              4              5               6
2.5 kb
2 kb
Figure 1. Screening of the clones by PCR amplification. 
Lane 1: negative control, lane 2: negative clone, lanes 3, 4 and 5: PCR 
product of positive clones, lane 6: 1kb DNA ladder.
 
2.5 kb
2 kb
1                2               3             4                5              6
Figure 2. Restriction digestion analysis of positive clones. 
Lane 1: undigested pMAL-c2X, lane 2: pMAL-c2X digested by 
BamHI, lanes 3, 4 and 5: pMAL-c2X-PA digested by BamHI and 
SalI, lane 6: 1 kb DNA ladder.
3.3. Expression of rMBP-PA fusion protein
  After Coomassie Blue staining, a protein band with 
expected molecular weight of about 125 kDa was obtained, 
when compared to the uninduced and control samples(Figure 
3). The expression of rMBP-PA fusion protein was also 
confirmed by Western blot analysis using anti-PA 
monoclonal antibody (Figure 4). Western blotting detected a 
band at the expected position and the rPA was recognized by 
anti-PA antibody. In the uninduced and control samples, no 
reaction was observed.
117 kDa
85  kDa
48  kDa
34  kDa
26  kDa
19  kDa
MBP-PA
1           2          3        4          5        6          7
Figure 3. SDS-PAGE analysis of the MBP-PA fusion protein 
expression in E. coli DH5毩 host. 
Lane 1: protein molecular weight marker, lane 2: negative clone 
(pMAL-c2X) before IPTG induction, lane 3: negative clone after 
induction, lane 4: positive clone (pMAL-c2X-PA) before induction, 
lanes 5, 6 and 7: positive clone 2, 4 and 6 h after induction.
MBP-PA
  1          2        3           4        5          6           7 
117 kDa
85 kDa
Figure 4. Western blot analysis of the MBP-PA fusion protein 
expression. 
Lane 1, 2 and 3: positive clone (pMAL-c2X-PA) 6, 4 and 2 h after 
induction, lane 4: protein molecular weight marker, lane 5: positive 
clone before induction, lane 6: negative clone (pMAL-c2X) before 
induction, lane 7: nagative clone after induction.
4. Discussion
  Anthrax is a serious problem in developing countries 
and occurs among animals and humans. The current 
threat of anthrax is potential use as a biological weapon 
and B. anthracis is an attractive agent for this purpose[13]. 
Thus, vaccination of humans against anthrax is essential. 
The current available PA-based vaccines have several 
disadvantages and are not ideal for human immunization[17]. 
For these reasons, a new vaccine should be improved, 
safe, cheap, and effective against all forms of anthrax 
infection (cutaneous, inhalational, and gastrointestinal). 
One of  the toxin components is PA, which translocates 
LF and EF into the cytoplasm of the target cell[7,8]. PA is 
an essential component for designing an effective anthrax 
vaccine and anti-PA antibodies induce protection against 
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disease. Antibodies against PA could inhibit the toxin 
function and germination of spores[6, 19]. Therefore, the PA 
gene has been expressed in several expression systems 
including E. coli[20,21], Bacillus subtilis (B. subtilis)[22], Bacillus 
brevis (B. brevis)[23], Baculovirus, and Vaccinia virus[24]. 
Recently, the most production of PA has been reported 
from E. coli, approximately 370 mg/mL of culture[21]. In 
the present study, we used the pMAL expression system 
for high expression of PA in E. coli. The results showed 
that the PA gene was cloned successfully downstream to 
the malE gene of E. coli and expressed as a fusion protein 
with MBP of E. coli. The expected MBP-PA fusion protein 
was expressed with a molecular weight of about 125 kDa 
and observed in SDS-PAGE analysis. The fusion protein 
identity was also confirmed by Western blotting using 
monoclonal antibody. The pMAL expression and purification 
system has the following advantages: 1) protein expression 
is controlled by the strong tac promoter and induced in 
the presence of IPTG, 2) the recombinant fusion protein is 
purified by one-step purification using affinity for maltose 
that facilitate purification process of foreign protein and 3) 
the pMAL-c2X vector encodes a site for factor Xa, which 
cleaves MBP from the fusion protein after purification. 
In most cases, the pMAL-c2X plasmid expresses fusion 
protein, which approximately constitutes 20%-40% of the 
total cellular protein. In the present study, Western blot 
analysis indicated that proteolysis of induced fusion protein 
increased with IPTG induction time. 
  In conclusion, we successfully expressed B. anthracis PA 
(83 kDa)  at high level in the E. coli DH5毩 strain. Further 
studies including purification and immunization in animal 
models will be done to evaluate potential of the purified PA 
as a recombinant vaccine. This antigen could also employ in 
anthrax diagnostic tests and laboratory research.
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